Detected ·
Golgenia
€1.5M—
Golgenia, Italian biotech focused on developing new therapeutic strategies against cancer, has closed a €1.5M Series A round. The round saw participation from Indaco SGR through the Indaco Bio Lombardia Parallel Fund, supported by Regione Lombardia's Lombardia Venture STEP initiative. The funding will allow Golgenia to accelerate development of its main therapeutic compound and launch its first pilot clinical trial.
- Website
- —
- —
- Amount
- €1 500 000 EUR
- Stage
- —
- Event
- Funding round
- Detected
- 2026-08-11 20:03:37 UTC
- Signal ID
- b03017c2-2592-4ebb-91f0-9621115d33a1
As the API returns it
{
"id": "b03017c2-2592-4ebb-91f0-9621115d33a1",
"created_at": "2026-08-11T20:03:37.768328Z",
"company_name": "Golgenia",
"company_website_url": null,
"company_linkedin_url": null,
"event_type": "funding",
"funding_amount": 1500000,
"funding_currency": "EUR",
"funding_stage": null,
"message": "*Golgenia, Italian biotech focused on developing new therapeutic strategies against cancer, has closed a €1.5M Series A round. The round saw participation from Indaco SGR through the Indaco Bio Lombardia Parallel Fund, supported by Regione Lombardia's Lombardia Venture STEP initiative. The funding will allow Golgenia to accelerate development of its main therapeutic compound and launch its first pilot clinical trial.*"
}